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Experimental study in animals. Introduction: Mitomycin 
C has been used as a fibroblasts inhibitor, thus reducing 
the scaring process in surgical wounds. Aim: This paper 
aims at assessing the use of Mitomycin C to reduce the 
scaring process through its topical use and later injected 
reinforcements. Materials and Methods: We used a model 
of a creating a wound in the dorsum of rats, removing a 
circular piece of skin and letting it heal by itself. We used 
18 rats, divided in three groups. The first group - Control, 
the second with topical use, and a third group with injected 
mitomycin C reinforcement, monthly for 2 months. After 3 
months the animals were slaughtered and the scars were 
surgically removed and sent for histology study. Results: 
We noticed, under different criteria, that healing with topical 
mitomycin is less intense; however, when it was injected, the 
parameters were again comparable to those from the control 
group. Discussion: We believe that injected mitomycin C in 
the scar, since it is highly toxic, it destroys tissue and brings 
about scar neoformation. Conclusions: Mitomycin C reduces 
the scaring process when used topically; however, it increases 
scar tissue formation when injected in these wounds. 
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INTRODUCTION
Mitomycin-C has been broadly used as a chemo-
therapeutic agent1. Lately, however, its role as a fibro-
blast inhibitor2 in delaying the healing process has been 
explored in surgical procedures where sequelae such as 
stenosis and adhesion may occur. A number of papers in 
the literature have shown such effect in surgical settings, 
many of which in otorhinolaryngology3-7. Studies with 
animal models have also been conducted8,9, but consen-
sus has not been reached and contradictory evidences 
question its true efficacy. Many papers have shown that 
topical mitomycin-C alone might fail to achieve the desired 
results10. Injections of the agent have therefore been added 
to strengthen its effectiveness and to further mitigate the 
occurrence of surgical fibrosis11-13. 
OBJECTIVE
This paper aims to compare the responses of rat 
wound models where mitomycin-C was applied topically 
alone or topically in conjunction with monthly reinforce-
ment injections.
MATERIALS AND METHODS
This paper was approved by the animal studies 
ethics committee of the institution, under permit # 10 of 
May 14, 2002. Eighteen young male Wistar rats weighing 
between 355 and 400 grams were used. The animals were 
kept in separate cages in the lab of the Surgical Technique 
Unit of the institution. The rats were anesthetized with 
Ketamine (Francotar®) 10ml in concentrations of 100mg/
ml and doses of 0.5 ml/rat and Xylazine (Rompun®) 
10ml in concentrations of 20mg/ml and doses of 0.1ml/
rat. While under general anesthesia, the rats had identical 
wounds of two centimeters in diameter made in their 
dorsa. All eighteen rats were numbered and divided into 
three groups of six subjects each. The control group had 
their wounds treated topically with gauze soaked in saline 
solution for five minutes. The wounds of the remaining 
two groups were treated with gauze soaked in one millili-
ter of mitomycin-C in concentrations of 0.5ml/mg for five 
minutes and then washed with 10 ml of saline solution. 
Every thirty days - twice in all - the subjects on group 
three were injected a 0.01mg/ml solution of mitomycin-C 
into their scars. Equal volumes of saline solution were 
injected in the subjects of the two remaining groups. The 
adopted topical concentration was based in the values 
reported in the literature10,13. A previous paper indicated 
that the injection concentration used in this study would 
not result in rat tissue necrosis11. Two rats in the control 
group died as they were being anesthetized. All rats were 
slaughtered after 90 days (intracardiac injection of 19.1% 
KCl after general anesthesia), their scars surgically remo-
ved and sent for histology. The specimens were randomly 
numbered and sent to the pathologist who examined, 
embedded, sliced, and stained them with H&E. The slides 
were assessed in terms of the degree of fibrosis, vascular 
proliferation, number of fibroblasts and fibrocytes.
RESULTS
The slides were analyzed and each parameter was 
given a +, ++ or +++ rating, depending on the intensity of 
the outcome. The results can be seen in Chart 1.
Chart 1. Rat wound assessment in terms of fibrosis, vascular prolife-




Scar tissue intensity may be characterized by the 
degree of fibrosis present in it.
 
Vascular proliferation




The greater the number of fibroblasts, the less ma-
ture and established is the healing process.
 
Number of fibrocytes
The greater the number of fibrocytes, the older and 
more intense is the scar.
As seen in the chart, the subjects in group 2 - topi-
cal mitomycin-C alone - have presented the least intense 
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and developed scar tissues. Group 3 - topical and injected 
mitomycin-C - was expected to have an even more inci-
pient formation of scar tissue, as its subjects were given 
an additional shot of mitomycin-C every thirty days, but 
healing was nonetheless more intense. This is possibly 
due to the high toxicity and necrotizing characteristics 
of mitomycin-C. Therefore, every thirty days the healing 
tissue would be attacked, which led the healing process 
to start all over again. Perhaps the already quite low 
concentration of 0.01ml/mg could be further reduced to 
yield better results. The mechanical impact of the injection 
was disregarded, as all other groups were given the same 
number of shots and same volume of saline solution.
The low number of subjects rendered the statisti-
cal assessment attempts impractical. The + rating system 
was thus also adopted for this parameter. The ratings for 
each rat were given based on the parameter assessed in 
relation to the healing degree. Pluses (+) were given to 
fibrosis and fibrocytes scores and minuses (-) to vascular 





4: +2-2-2+1= - 1
5:+1-3-3+1= - 4
6:+1-3-3+2= - 3
7: +1-3-3+1= - 4
8: +1-3-2+1= - 3
9: +1-3-3+2= - 3
10: +2-1-1+3= + 3
11: +2-1-2+3= + 2
12: +1-3-3+1= - 4
13: +3-1-2+3= + 3
14: +3-2-1+3= + 3
15: +3-1-1+3=+ 4
16: +3-1-1+3= + 4
The summation of the scores for subjects one to 
four (control group) was -2.
The summation of the scores for subjects five to 
ten (topical) was -14.
The summation of the scores for subjects eleven to 
sixteen (topical + injection) was +12.
After removing the most discrepant subjects from 
the groups (number 3 from the control group, number 10 
from the topical treatment group, and number 12 from 
the topical treatment + injection group), the results were 
as follows:
Control group: -6
Topical treatment group: -17
Topical treatment + injection: +16
Thus, considering that healing can be assessed as 
more intense when more fibrosis and fibrocytes are present 
(+) and less intense when more vascular proliferation and 
fibroblasts are present (-), it was realized that after 90 days 
of treatment the group using only topical mitomycin-C had 
comparatively less healing than the control group, while 
the group under the topical treatment and injection regi-
men had much more intense scar tissue formation.
One should notice that the large number of fibro-
blasts and extensive vascular proliferation found in the 
topical mitomycin-C group after 90 days of treatment has 
yielded laxer and more fragile scar tissues. A longer term 
study is thus necessary to verify whether such trait will 
persist.
CONCLUSIONS
After 90 days of treatment, mitomycin-C was shown 
to be more effective in controlling the healing process 
when used only topically. When injected every 30 days for 
the duration of the experiment, healing was more intense 
than observed in the control group.
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